Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | PRNP | P04156 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.32 |
| ▸ | TERT | O14746 | 5/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MAP2 | P11137 | 3/20 | 0.31 |
| ▸ | BCL6 | P41182 | 1/20 | 0.30 |
| ▸ | BCOR | Q6W2J9 | 1/20 | 0.30 |
| ▸ | RAD52 | P43351 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5117583 | 0.81 | KIF11 (0.44) | KDM4EPRNPP2RY12TERTALDH1A1 | |
| SCHEMBL5066580 | 0.80 | NPSR1 (0.44) | KDM4EPRNPHSD17B10MAP2RAD52 | |
| SCHEMBL5117028 | 0.75 | NGFR (0.40) | KDM4EPRNPALDH1A1HPGDMAP2 | |
| SCHEMBL5109529 | 0.74 | MAPK1 (0.36) | MAP2CXCR2 | |
| SCHEMBL2983431 | 0.71 | MAP2 (0.51) | KDM4EALDH1A1HPGDMAP2 | |
| SCHEMBL5121688 | 0.68 | SPR (0.39) | KDM4EALDH1A1HPGDHSD17B10MAP2 | |
| SCHEMBL5122341 | 0.67 | BLM (0.38) | KDM4EALDH1A1ALOX15HSD17B10MAP2 | |
| SCHEMBL7079051 | 0.66 | SPR (0.37) | KDM4EALDH1A1HPGDHSD17B10MAP2 | |
| SCHEMBL6783853 | 0.65 | KDM4E (0.40) | KDM4EALDH1A1HPGDHSD17B10MAP2 | |
| SCHEMBL5773028 | 0.65 | BLM (0.53) | KDM4EALDH1A1HPGDALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301487-B1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM CA LTD (CA) | 2006-11-22 | — | — | EP | disclosed |
| US-20030232816-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-12-18 | — | — | US | disclosed |
| US-6479508-B1 | INHIBITOR OF RNA DEPENDENT RNA POLYMERASE ACTIVITY OF THE ENZYME NS5B ENCODED BY HEPATITIS C VIRUS FOR TREATMENT AND PREVENTION OF HEPATITIS C INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232816-A1 | Viral polymerase inhibitors | POLR2H, POLR2E, POLM | KDM4E 2381/4885PRNP 235/4885P2RY12 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.